BiotechTube

QBW251 + Placebo

Phase 2Terminated
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Bronchiectasis

Conditions

Bronchiectasis

Trial Timeline

Feb 2, 2021 → Jun 21, 2023

NCT ID
NCT04396366

About QBW251 + Placebo

QBW251 + Placebo is a phase 2 stage product being developed by Novartis for Bronchiectasis. The current trial status is terminated. This product is registered under clinical trial identifier NCT04396366. Target conditions include Bronchiectasis.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (3)

NCT IDPhaseStatus
NCT04396366Phase 2Terminated
NCT04268823Phase 2Terminated
NCT02449018Phase 2Completed

Competing Products

20 competing products in Bronchiectasis

See all competitors
ProductCompanyStageHype Score
Benralizumab + Placebo to BenralizumabAstraZenecaPhase 3
77
AZD9668 + PlaceboAstraZenecaPhase 2
52
AZD5069 + PlaceboAstraZenecaPhase 2
52
AZD0292AstraZenecaPhase 2
52
TIP + TIP and placebo + PlaceboNovartisPhase 2
52
Ciprofloxacin DPI (BAYQ3939) + PlaceboNovartisPhase 3
77
Placebo to Ciprofloxacin DPI (BAYQ3939)NovartisPre-clinical
23
Ciprofloxacin (BAYQ3939) dry powder for inhalation + Ciprofloxacin (BAYQ3939) dry powder for inhalation + Placebo + PlaceboNovartisPhase 3
77
Ciprofloxacin (Cipro, BAYQ3939) + PlaceboNovartisPhase 2
52
AZLI + PlaceboGilead SciencesPhase 3
76
Aztreonam lysineGilead SciencesApproved
84
AZLIGilead SciencesPhase 2
51
AZLI + PlaceboGilead SciencesPhase 3
76
Itepekimab (SAR440340) + PlaceboSanofiPhase 2
51
CSL787 + PlaceboCSLPhase 1
32
CSL787 + PlaceboCSLPhase 2
51
HSK31858, tablet + PlaceboHaisco Pharmaceutical GroupPhase 3
74
HSK31858 + placeboHaisco Pharmaceutical GroupPhase 2
49
Group A + Group BBayerPre-clinical
20
BAY85-8501 + PlaceboBayerPhase 2
49

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85